Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories
-
Amarin to Participate in September Investment Conferences
-
Amarin Corporation (AMRN) Symphony Data Shows Vacepta in Uptrend - Cantor Fitzgerald
-
Amarin Corporation's (AMRN) Vascepta Symphony Health Numbers are Increasing Meaningfully - Cantor Fitzgerald
-
Cantor Reiterates Overweight on Amarin (AMRN) as Recent Concerns are 'Overdone'
-
Pre-Open Stock Movers 01/22: (ADMP) (CLII) (SCYX) Higher; (PGEN) (IBM) (GSL) Lower (more...)
-
After-Hours Stock Movers 01/21: (ADMP) (IBIO) (FLDM) Higher; (PGEN) (IBM) (GSL) Lower (more...)
-
Amarin Corporation (AMRN) Symphony Data Shows Continuing Improvement - Cantor Fitzgerald
-
Amarin (AMRN) Retaining EU Rights 'The Right Thing to Do' - Cantor Fitzgerald
-
Cantor Fitzgerald Said Amarin (AMRN) NDR Supports Bullish Rating, PT
-
Companies with NDRs 7/08
-
Amarin (AMRN) Continues to Offer 'Sweets' - Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Amarin Corporation (AMRN) Following Conference Call
-
Two Pieces of Good News for Amarin (AMRN) - Cantor Fitzgerald
-
Cantor Fitzgerald Defends Amarin (AMRN), Says Headlines 'Noise'
-
Amarin Corporation (AMRN) Updated Guidance In Line, Cantor Fitzgerald Reiterates Outperform
-
Amarin Corporation (AMRN) Expenses May Drive Expenses Higher but Vascepa Peak Sales Remains the Key for Investors - Cantor Fitzgerald
-
Health Canada Approval Underscores Global Market Opportunity for Amarin's (AMRN) Vascepa - Cantor Fitzgerald
-
Amarin's (AMRN) Vascepa Rxs Continue To Show Positive Trends - Cantor Fitzgerald
-
Amarin (AMRN) Vascepa Checks Another Box with EMA Acceptance - Cantor Fitzgerald
-
Cantor Fitzgerald Expects Shares of Amarin (AMRN) to Rise After 16-0 Favorable FDA Adcom Vote
-
Amarin Corporation (AMRN) Beats but Vascepa Remains Underappreciated - Cantor
-
Cantor Fitzgerald Positive on Amarin (AMRN) As Generics Lose On Summary Judgement
-
Cantor Fitzgerald Reiterates Positive View on Amarin (AMRN) Following Final ICER Report
-
Amarin Corporation (AMRN) Symphony Data On An Uptrend - Cantor Fitzgerald
-
NLA Provides Amarin's (AMRN) Vascepa With Yet Another Positive Recommendation - Cantor Fitzgerald
-
Visibility on Amarin (AMRN) sNDA Removes Overhang - Cantor Fitzgerald
-
Amarin Corporation (AMRN): AdCom and sNDA Concerns are Overdone - Cantor Fitzgerald
-
Amarin Corporation (AMRN) Reiterated Overweight At Cantor Fitzgerald
-
Amarin Corporation (AMRN) - Negative Reaction To AdCom Is Overdone - Cantor
-
Cantor Fitzgerald Reiterates Overweight Rating on Amarin Corporation (AMRN)
-
Amarin Announces Underwriters’ Full Exercise of Option to Purchase Additional American Depositary Shares
-
Amarin Announces Underwriters’ Full Exercise of Option to Purchase Additional American Depositary Shares
-
Cantor Fitzgerald Notes Amarin (AMRN) Pharmacoeconomic Analysis Results 'Is ICER-ing On The Cake'
-
Amarin Corporation's (AMRN) Peak Sales Could Exceed Great Expectations - Cantor
-
Amarin Corp. (AMRN) Prices 22.22M ADS Offering at $18/ADS
-
Amarin Prices Public Offering of American Depositary Shares
-
Amarin Prices Public Offering of American Depositary Shares
-
Amarin Corp. (AMRN) Announces Proposed $400M ADS Offering
-
Amarin Announces $400,000,000 Public Offering of American Depositary Shares
-
Amarin Announces $400,000,000 Public Offering of American Depositary Shares
-
Amarin Corporation (AMRN) Should Benefit from Strong Vascepta Script Data - Cantor
-
Amarin Corporation (AMRN) Scripts May Be Underrepresented By Script Data - Cantor
-
Cantor Fitzgerald Reiterates Overweight Rating on Amarin Corporation (AMRN)
-
Amarin (AMRN) Vascepa RXs Outpace Industry as of 06/07 - Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Amarin (AMRN) Following Latest Vascepa Rxs
-
Cantor Fitzgerald Reiterates Overweight Rating on Amarin (AMRN) Following Priority Review
-
Amarin Corp. (AMRN) Ends Blockbuster Week with a Bang
-
Amarin Corporation (AMRN) Inclusion In ADA Standards A Significant Positive - Cantor
-
Amarin Corporation (AMRN) ACC Presentation Supports Economic Value For Vascepa - Cantor
-
Amarin (AMRN): Potential Takeout And Positive Rx Trends Support Positive Thesis - Cantor Fitzgerald